Get the Stockscreener App
0.6242
1.70%
-0.0108
After Hours:
.63
0.0058
+0.93%
Tempest Therapeutics Inc stock is traded at $0.6242, with a volume of 66,109.
It is down -1.70% in the last 24 hours and down -48.41% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
See More
Previous Close:
$0.635
Open:
$0.668
24h Volume:
66,109
Relative Volume:
0.37
Market Cap:
$10.54M
Revenue:
Net Income/Loss:
$-43.10M
P/E Ratio:
-0.1005
EPS:
-6.2098
Net Cash Flow:
$-26.38M
1W Performance:
-17.88%
1M Performance:
-48.41%
6M Performance:
-72.13%
1Y Performance:
-88.74%
1-Day Range:
$0.6201
$0.6688
1-Week Range:
$0.6201
$0.7775
52-Week Range:
$0.6201
$5.99
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
0.6242 | 10.54M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
With $0 left to sell, Tempest Therapeutics (TPST) reports a warrant offering. - Stock Titan
Nancy Freda Smith Files Initial SEC Ownership Disclosure as New Director of Tempest Therapeutics - Kalkine Media
A director receives 25,000 options with a $1 exercise price at Tempest Therapeutics (TPST). - Stock Titan
Avalo Therapeutics, Inc. (AVTX) Stock Price, News, Quote & History - Yahoo Finance
Form 8K Tempest Therapeutics Inc For: 28 September By Investing.com - Investing.com Australia
Form 8K Tempest Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 8K Tempest Therapeutics Inc For: 28 September By Investing.com - Investing.com South Africa
Form 8K Tempest Therapeutics Inc For: 28 September By Investing.com - Investing.com UK
Tempest Therapeutics, Inc. (TPST) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tempest Therapeutics, Inc.Common Stock (NQ: TPST - The Chronicle-Journal
TPST Stock Slides As Dilutive Financing Overhang Builds - StocksToTrade
TPST Stock Spikes As Tempest Therapeutics Expands In Vivo CAR-T Pipeline - timothysykes.com
TPST Stock Jumps As Tempest Therapeutics Expands CAR-T Pipeline - timothysykes.com
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket - Benzinga
TPST Stock Spikes As Tempest Therapeutics Bets On In Vivo CAR-T - StocksToTrade
TPST Stock Spikes As Tempest Therapeutics Expands In Vivo CAR-T Pipeline - Timothy Sykes
Tempest Therapeutics Raises $2.5 Million in Private Placement - Minichart
Form 8K Tempest Therapeutics Inc For: 15 September By Investing.com - Investing.com UK
Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang - Yahoo Finance
Tempest Therapeutics raises $2.5M in private placement By Investing.com - Investing.com Australia
Tempest Therapeutics raises $2.5M in private placement By Investing.com - Investing.com Nigeria
Tempest Therapeutics, Inc. announced that it expects to receive $2.500001 million in funding - marketscreener.com
Tempest Therapeutics Announces Up to $7.5 Million Private Placement - markets.businessinsider.com
Tempest Therapeutics raises $2.5M in private placement By Investing.com - Investing.com Canada
Tempest Therapeutics raises $2.5M in private placement - Investing.com
Tempest Therapeutics raises $2.5M in private placement By Investing.com - Investing.com India
Tempest Therapeutics Announces Up to $7.5 Million Private Placement - The Manila Times
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Tempest Therapeutics raises $2.5M in private placement By Investing.com - Investing.com UK
Tempest Therapeutics Announces Up to $7.5 Million Private Placement - GlobeNewswire
Tempest Therapeutics Announces Up to $7.5 Million Private Placement - Yahoo Finance
Tempest Therapeutics CEO to present at H.C. Wainwright Global Investment Conference - Bitget
A biotech CEO will speak Sept. 15; Tempest will archive the webcast - Stock Titan
Tempest Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Tempest Therapeutics (TPST) Slips 1.85% to $1.06 as Shares Test Support at $1.01Cup and Handle - siam.in
Tempest Therapeutics (TPST) Slips 1.85% to $1.06 as Shares Test Support at $1.01Large Cap Trends - dars.gov.et
Tempest TherapeuticsJustin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1SEC Filing - tradingview.com
Tempest (TPST) Results at a Glance: Reported EPS Misses Expectations at the Close; Trading Move: The Stock Records a 1.96% Increase in Latest TradingProfit Guidance Range - vinanet.vn
Tempest Therapeutics secures $50M equity purchase agreement with Lincoln Park - scanx.trade
Tempest Therapeutics files prospectus for sale of 8.9 million shares - scanx.trade
Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan
Tempest (TPST) Results Versus Estimates: The EPS Result Is Below Expectation in Latest Trading; Latest Reaction: The Stock Loses 4.58% in the Available RecordProfit Recovery Report - vinanet.vn
Tempest partners Senlang to advance TPST-4003 in China trial - scanx.trade
Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Tempest Therapeutics adjourns special meeting, sets new date for stockholder vote - Investing.com
Tempest Therapeutics Adjourns Special Stockholder Meeting Again - TipRanks
Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com Nigeria
Tempest Therapeutics adjourns special meeting, sets new date for stockholder vote - Investing.com
Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com Canada
Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com India
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tempest Therapeutics Inc Stock (TPST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Angel Matthew | CEO and President |
Mar 24 '26 |
Buy |
2.16 |
231,482 |
500,001 |
231,482 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):